Piperidinone derivatives as MDM2 inhibitors for the treatment of cancer

US9593129B2 · kind B2 · utility

Assignee

• AMGEN INC. · US

Inventors

• Michael D. Bartberger · West Hollywood, US
• Ana Z. Gonzalez Buenrostro · San Mateo, US
• Hilary Plake Beck · Emerald Hills, US
• Xiaoqi Chen · Palo Alto, US
• Richard V. Connors · Mesa, US
• Jeffrey Deignan · San Francisco, US
• Jason A. Duquette · Millbrae, US
• John Eksterowicz · Burlingame, US
• Benjamin Fisher · San Mateo, US
• Brian M. Fox · Brisbane, US
• Jiasheng Fu · Foster City, US
• Zice Fu · Foster City, US
• Felix Gonzalez Lopez De Turiso · San Mateo, US
• Michael W. Gribble, Jr. · San Francisco, US
• Darin J. Gustin · Rue de l'Église, US
• Julie Anne Heath · Chico, US
• Xin Huang · Brookline, US
• XianYun Jiao · Belmont, US
• Michael G. Johnson · San Diego, US
• Frank Kayser · San Francisco, US
• David John Kopecky · West Hollywood, US
• SuJen Lai · Burlingame, US
• Yihong Li · Millbrae, US
• Zhihong Li · San Jose, US
• Jiwen Liu · Winston-Salem, US
• Jonathan D. Low · Thousand Oaks, US
• Brian S. Lucas · Arlington, US
• Zhihua Ma · Lexington, US
• Lawrence R. McGee · Pacifica, US
• Joel McIntosh · Pacifica, US

Key dates

• Filing date: Jan 27, 2016
• Grant date: Mar 14, 2017
• Expiry date: Jan 27, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D498/20
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present invention provides MDM2 inhibitor compounds of Formula I,